214 related articles for article (PubMed ID: 32113624)
1. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
[TBL] [Abstract][Full Text] [Related]
2. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
Fenwick E; Steuten L; Knies S; Ghabri S; Basu A; Murray JF; Koffijberg HE; Strong M; Sanders Schmidler GD; Rothery C
Value Health; 2020 Feb; 23(2):139-150. PubMed ID: 32113617
[TBL] [Abstract][Full Text] [Related]
3. Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana.
Gad M; Lord J; Chalkidou K; Asare B; Lutterodt MG; Ruiz F
Value Health; 2020 Feb; 23(2):171-179. PubMed ID: 32113622
[TBL] [Abstract][Full Text] [Related]
4. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
5. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
Grimm SE; Strong M; Brennan A; Wailoo AJ
Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
[TBL] [Abstract][Full Text] [Related]
6. Scenario drafting to anticipate future developments in technology assessment.
Retèl VP; Joore MA; Linn SC; Rutgers EJ; van Harten WH
BMC Res Notes; 2012 Aug; 5():442. PubMed ID: 22894140
[TBL] [Abstract][Full Text] [Related]
7. Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
Rothery C; Strong M; Koffijberg HE; Basu A; Ghabri S; Knies S; Murray JF; Sanders Schmidler GD; Steuten L; Fenwick E
Value Health; 2020 Mar; 23(3):277-286. PubMed ID: 32197720
[TBL] [Abstract][Full Text] [Related]
8. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
[TBL] [Abstract][Full Text] [Related]
9. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
Wallerstedt SM; Henriksson M
Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
11. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
Pinto A; Naci H; Neez E; Mossialos E
Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
[TBL] [Abstract][Full Text] [Related]
12. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
[TBL] [Abstract][Full Text] [Related]
13. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
14. Exploring structural uncertainty in model-based economic evaluations.
Afzali HH; Karnon J
Pharmacoeconomics; 2015 May; 33(5):435-43. PubMed ID: 25601288
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis.
Leelahavarong P
J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
[TBL] [Abstract][Full Text] [Related]
16. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
17. Differences in cancer drug assessment between Spain and the United Kingdom.
Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
[TBL] [Abstract][Full Text] [Related]
18. Modeling for health care and other policy decisions: uses, roles, and validity.
Weinstein MC; Toy EL; Sandberg EA; Neumann PJ; Evans JS; Kuntz KM; Graham JD; Hammitt JK
Value Health; 2001; 4(5):348-61. PubMed ID: 11705125
[TBL] [Abstract][Full Text] [Related]
19. Implementing managed entry agreements in practice: The Dutch reality check.
Makady A; van Veelen A; de Boer A; Hillege H; Klungel OH; Goettsch W
Health Policy; 2019 Mar; 123(3):267-274. PubMed ID: 30316540
[TBL] [Abstract][Full Text] [Related]
20. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.
Li M; Basu A; Bennette C; Veenstra D; Garrison LP
Value Health; 2019 Jul; 22(7):777-784. PubMed ID: 31277824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]